Mouse Abcb1a activation kit by CRISPRa

CAT#: GA203201

Abcb1a CRISPRa kit - CRISPR gene activation of mouse ATP-binding cassette, sub-family B (MDR/TAP), member 1A



  See Other Versions

CNY 12,255.00


货期*
4周

规格
    • 1 kit

Product images

Specifications

Product Data
Format 3 gRNAs (5ug each), 1 scramble ctrl (10ug) and 1 enhancer vector (10ug)
Symbol Abcb1a
Locus ID 18671
Kit Components

GA203201G1, Abcb1a gRNA vector 1 in pCas-Guide-GFP-CRISPRa

GA203201G2, Abcb1a gRNA vector 2 in pCas-Guide-GFP-CRISPRa

GA203201G3, Abcb1a gRNA vector 3 in pCas-Guide-GFP-CRISPRa

1 CRISPRa-Enhancer vector, SKU GE100056

1 CRISPRa scramble vector, SKU GE100077

Disclaimer These products are manufactured and supplied by OriGene under license from ERS. The kit is designed based on the best knowledge of CRISPRa SAM technology. The efficiency of the activation can be affected by many factors, including nucleosome occupancy status, chromatin structure and the gene expression level of the target, etc.
Reference Data
RefSeq NM_011076
Synonyms Abcb4; Evi32; mdr-3; Mdr1a; Mdr3; P-gp; Pgp; Pgy-3; Pgy3
Summary The membrane-associated protein encoded by this gene is a member of the superfamily of ATP-binding cassette (ABC) transporters. ABC proteins transport various molecules across extra- and intra-cellular membranes. ABC genes are divided into seven distinct subfamilies (ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, White). This protein is a member of the MDR/TAP subfamily. Members of the MDR/TAP subfamily are involved in multidrug resistance as well as antigen presentation. This gene encodes a p-glycoprotein which actively transports a variety of hydrophobic amphipathic drugs and plays a major role in the blood-brain barrier permeability of certain drugs. [provided by RefSeq, Jul 2008]
*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.

Documents

Other Versions

Customer Reviews 
Loading...